Last reviewed 2026-04-20 · How we verify

Zilbrysq

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: SERIOUS MENINGOCOCCAL INFECTIONS ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at l

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Diarrhea
• Urinary tract infection
• Nausea or vomiting
• Lipase increased
• Amylase increased
• Morphea
• Blood eosinophils elevated

Serious adverse events

• Meningococcal infections
• Pancreatitis
• Pancreatic cysts

Key clinical trials

• Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.